Casma to advance muscle dystrophy candidate into the clinic with $50M series B

A $50 million series B round led by The Column Group will provide Casma with enough cash to bring its lead Duchenne muscular dystrophy program into the clinic in early 2022. 

Launched in 2018, Casma evaluates the entire autophagy pathway for a broad swath of diseases (see “Tailoring Autophagy Targets to Indications”)...